Pacira BioSciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Pacira BioSciences Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.
Executive BD thesis
Pacira BioSciences is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 21 records at the decision date. The lead returned asset is Bupivacaine liposome, associated with SCNA and Pain, Postoperative, Back Pain, Osteoarthritis, Knee, Pain, at Approved. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.
A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Bupivacaine liposome | Pacira Biosciences, Inc. | Approved | Pipeline record: SCNA; Pain, Postoperative, Back Pain, Osteoarthritis, Knee, Pain. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Zimmer, Inc. offers to acquire Pacira CryoTech, Inc. | Approved asset with SCNA exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 2 | Triamcinolone Acetonide | Pacira Biosciences, Inc. | Approved | Pipeline record: GR; Osteoarthritis, Knee, Osteoarthritis, Hip, Diabetes Mellitus, Type 2. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets | Approved asset with GR exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 3 | Enekinragene inzadenovec | Pacira Biosciences, Inc. | Phase 2 | Pipeline record: IL-1RA; Osteoarthritis, Knee. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio | Phase 2 asset with IL-1RA exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 4 | Funapide | Flexion Therapeutics, Inc. | Phase 2 | Pipeline record: Nav1.7 x Nav1.8; Neuralgia, Postherpetic, Bunion, Pain, Postoperative. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Zimmer, Inc. offers to acquire Pacira CryoTech, Inc. | Phase 2 asset with Nav1.7 x Nav1.8 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 5 | GQ-303 | GeneQuine Biotherapeutics GmbH | Preclinical | Pipeline record: PRG4; Osteoarthritis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets | Preclinical asset with PRG4 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-06-30 | Zimmer, Inc. offers to acquire Pacira CryoTech, Inc. | Active | Not disclosed |
| 2026-01-13 | Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets | Active | Not disclosed |
| Not returned | Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio | Completed | Not disclosed |
Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.
Financial capacity and partnering pressure
- Pacira BioSciences, Inc. - 2021 Quarterly report: Pacira BioSciences, Inc. - 2021 Quarterly report Liquidity and Capital Resources Pacira BioSciences, Inc.'s Condensed Consolidated Statements of Cash Flows for the years 2021 and 2020 reveal notable fluctuations in cash flow across various activities. In 2021, operating activities generated $12,081 in net cash, more than doubling the $6,208 generated in 2020. Conversely, investing activities in 2021 utilized a substantial $(55,664) in net cash, significantly exceeding the $(28,566) used in 2020. Financing activities, however, showed a marked improvement, providing $10,325 in net cash in 2021, a stark contrast to the $(1,281) used in 2020. Ultimately, these activities cumulatively resulted in a net decrease in cash and cash equivalents, with 2021 seeing a $(33,258) decrease, which, although larger in absolute terms, reflects a similar trend to the $(23,639) decrease observed in 2020. Paci
- Pacira BioSciences, Inc. - 2021 Annual report: Pacira BioSciences, Inc. - 2021 Annual report Results of Operations Pacira BioSciences, Inc.'s research and development (R&D) expenses for the year ended December 31, 2021, and the comparative period in 2020, are outlined as follows. Clinical and preclinical development costs increased by 4% to $24,139 in 2021 from $23,126 in 2020. Conversely, expenses related to product development and manufacturing capacity expansion decreased by 18% to $19,352 in 2021 from $23,516 in the prior year. Regulatory and other expenses also saw a decline of 13% to $6,590 in 2021 from $7,568 in 2020. Meanwhile, stock-based compensation expenses experienced a modest increase of 5% to $5,464 in 2021 from $5,211 in 2020. On a consolidated basis, total R&D expenses decreased by 7% to $55,545 in 2021 from $59,421 in the preceding year. Notably, the proportion of total revenue allocated to R&D decreased to 10% in 2
- Pacira BioSciences, Inc. - 2022 Quarterly report: Pacira BioSciences, Inc. - 2022 Quarterly report Clinical Development Programs Pacira BioSciences, Inc.'s Condensed Consolidated Statements of Cash Flows for the years 2022 and 2021 reveal notable fluctuations in cash flow across various activities. In 2022, operating activities generated $60,583 in net cash, a significant increase from the $42,215 generated in 2021. Conversely, investing activities in 2022 resulted in a substantial net cash outflow of $188,858, markedly higher than the $52,631 outflow in 2021. Financing activities also saw a considerable shift, with 2022 recording a net cash outflow of $335,242, contrasting with a net inflow of $16,233 in 2021. Ultimately, these activities cumulatively led to a net decrease in cash and cash equivalents of $463,517 in 2022, a stark contrast to the net increase of $5,817 observed in 2021. Pacira BioSciences, Inc. - 2022 Quarterly report C
Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.
Current-awareness events and outreach triggers
The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.
The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.
IP and freedom-to-operate risk screen
The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.
Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.
Recommended deal structures
- Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
- Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
- Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
- Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
- Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.
Outreach rationale and first-contact plan
- Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
- Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
- Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
- Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
- Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.
Decision memo
ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. Pacira BioSciences offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.
Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.
